Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study

Diabetologia
G BrunoP Cavallo-Perin

Abstract

Measurement of plasma apolipoprotein (Apo) B may improve prediction of cardiovascular risk, as it provides a measure of the total number of atherogenic particles. The aim of this population-based study was to compare the association of non-HDL-cholesterol, ApoB and the ApoB:ApoA-I ratio with cardiovascular mortality in people with type 2 diabetes. We assessed the association of lipids, lipoprotein lipids and apolipoproteins with 11-year mortality from cardiovascular disease in the population-based cohort of the Casale Monferrato Study (1,565 people with diabetes; median age 68.9 years), and determined the effect of age (< or =70 and >70 years) on these relationships. On the basis of 341 deaths from cardiovascular disease in 10,809 person-years of observation, there was a decreasing trend in risk adjusted for multiple factors across quartiles of total cholesterol, and LDL- and non-HDL-cholesterol in people aged >70 years, but no trend in those aged < or =70 years. Age did not affect the protective effect of HDL-cholesterol. ApoB and ApoB:ApoA-I were associated with outcome in people in both age groups independently of non-HDL-cholesterol. After adjustment for multiple factors, including non-HDL-cholesterol, the hazard ratios for...Continue Reading

References

Aug 16, 1995·JAMA : the Journal of the American Medical Association·M C CortiC H Hennekens
Mar 5, 1998·JAMA : the Journal of the American Medical Association·L P FriedJ M Gardin
Aug 11, 2000·Diabetes Care·E BrunUNKNOWN Verona Diabetes Study
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Nov 7, 2002·The American Journal of Cardiology·Allan D Sniderman
May 15, 2003·The American Journal of Cardiology·Allan D SnidermanBenoît Lamarche
Oct 21, 2003·The Annals of Pharmacotherapy·Kimberly A Dornbrook-LavenderMary T Roth
Jul 6, 2004·American Journal of Epidemiology·J David CurbKatsuhiko Yano
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program

❮ Previous
Next ❯

Citations

Oct 8, 2008·Nature Clinical Practice. Endocrinology & Metabolism·Jacqueline de GraafAllan Sniderman
Sep 3, 2013·The American Journal of Cardiology·Mohammed Al-HijjiSteven R Jones
May 4, 2010·Mayo Clinic Proceedings·Charles R Harper, Terry A Jacobson
Feb 27, 2007·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Graziella BrunoPaolo Cavallo-Perin
Nov 18, 2006·Clinics in Laboratory Medicine·Allan D Sniderman, Santica M Marcovina
Apr 28, 2012·Geriatrics & Gerontology International·Atsushi ArakiUNKNOWN Japanese Elderly Intervention Trial Research Group
Oct 11, 2020·International Journal of Environmental Research and Public Health·Raquel Pedrero-ChamizoMarcela González-Gross
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.